These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21362243)

  • 1. [Curative efficacy analysis of allo-HSCT using conditioning regimen of FLAG combined with modified BUCY for refractory and relapsed patients with hematologic malignancies].
    Wang ZH; Wu XX; Liu ZY; Ma J; Cao YB; Xu LX; Wu YM; Liu B; Yan B; DA WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):158-62. PubMed ID: 21362243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical analysis of high risk and refractory malignant hematologic diseases treated with haploidentical hematopoietic stem cell transplantation combined with umbilical cord mesenchymal stem cells using modified conditioning regimen].
    Wang ZH; Wu XX; Cao YB; Liu ZY; Xu LX; Li XH; Wu YM; Liu B; Yan B; Da WM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1224-7. PubMed ID: 24156439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Safety and effectiveness of tumor-ablative chemotherapy combined with low intensity modified conditioning regimen for 30 patients with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation].
    Luo RM; Da WM; Hu B; Si YJ; Zhang XM; Du ZL; Liu QH; Wang Y; Yue Y; Chen W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1047-52. PubMed ID: 25130826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases].
    Chen H; Lu DP; Huang XJ; Liu KY; Xu LP; Han W; Ren HY; Chen YH; Liu DH; Lu J; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2005 May; 26(5):273-6. PubMed ID: 15949287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
    Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies.
    Zhao XF; Mao XF; Wan DM; Liu W
    Transplant Proc; 2014 Jun; 46(5):1531-5. PubMed ID: 24935325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A preliminary study on efficacy of allogeneic hematopoietic stem cell transplantation by myeloablative conditioning regimen with fludarabine for high risk leukemia patients].
    Lu QY; Zaho JN; Niu XQ; Wang Z; Cai YX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):154-7. PubMed ID: 21362242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation].
    Chen F; Wu DP; Sun AN; Ma X; Tang XW; Qiu HY; Miao M; Fu ZZ; Jin ZM; Wang Y; Wu XJ; Chen SN; He GS; Wang XL; Xue SL; Zhao Y; Chang WR
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):83-6. PubMed ID: 18681306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma.
    Czajczynska A; Günther A; Repp R; Humpe A; Schub N; Raff T; Nickelsen M; Schrauder A; Schrappe M; Kneba M; Gramatzki M
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1632-7. PubMed ID: 23850653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of allogeneic hematopoietic stem cell transplantation in treatment of childhood myelogenous leukemia: the observation of 24 cases].
    Sun Y; Sun RJ; Wei ZJ; Xiao J; Zhang YC; Gao YQ; Zhu HL
    Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):813-6. PubMed ID: 23302609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
    Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia].
    Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of reduced conditioning intensity allo-HSCT treatment for relapsed ETO-positive AML].
    Guo Z; Chen HR; Liu XD; Lou JX; Yang K; Zhang Y; Chen P; He XP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1359-64. PubMed ID: 25338589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
    Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Salvaged allogeneic hematopoietic stem cell transplantation for refractory/recurrent acute myeloid leukemia].
    Wang JB; Wu T; DA WM; Tong CR; Sun Y; Zhao YL; Yin YM; Cao XY; Lu Y; Gao YQ; Zhou JR; Zhang JP; Luo RM; Zou W; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jun; 33(6):467-70. PubMed ID: 22967382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.